{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:45:31Z","timestamp":1754484331550},"reference-count":7,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Aging is tightly linked to chronic disease, frailty, and death.\n                    Multi-morbidity, defined as the presence in the same patient of three or more\n                    conditions such as neoplastic, cardiovascular, neurodegenerative, metabolic, or\n                    autoimmune diseases, becomes more common with age.<\/jats:p><jats:p>\n          Methods The study was performed in a double-blind fashion. Subjects within\n                    each dose cohort (Cohorts 1, 2, 3, and 4) were randomly assigned to receive\n                    Isomyosamine doses (between 150\u2009mg to 600\u2009mg or placebo) or\n                    placebo in a 3:1 ratio (6 active: 2 placebo).<\/jats:p><jats:p>\n          Results Isomyosamine single daily doses each of 150\u2009mg,\n                    300\u2009mg, and 450\u2009mg for 3 days and multiple daily doses of\n                    600\u2009mg for 6 days were safe and well tolerated in healthy subjects. In\n                    one dose group, there was a decrease in TNF-\u03b1 levels found in\n                    Isomyosamine treated subjects, but no change in the levels in subjects given\n                    placebo. The increase in Isomyosamine exposure was proportional to dose across\n                    the dose range of 300\u2009mg to 600\u2009mg when administered as a single\n                    dose. There was minimal accumulation of Isomyosamine following 5 days of once\n                    daily dosing of Isomyosamine 600\u2009mg. Isomyosamine half-life ranged from\n                    approximately 15\u2009minutes to 45\u2009minutes across all doses in the\n                    single ascending dose and multiple ascending dose portion of the study.\n                    Elimination of Isomyosamine included the renal pathway as a minor route.<\/jats:p><jats:p>\n          Conclusion Isomyosamine will continue to be investigated in phase 2\n                    clinical trials for the treatment of sarcopenia\/frailty,\n                    hashimoto\u2019s thyroiditis and rheumatoid arthritis.<\/jats:p>","DOI":"10.1055\/a-1962-6834","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:56:54Z","timestamp":1668214614000},"page":"95-104","source":"Crossref","is-referenced-by-count":1,"title":["A Double-blind, Placebo-controlled, Randomized, Single Ascending, and\n                    Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and\n                    Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult\n                    Subjects"],"prefix":"10.1055","volume":"73","author":[{"given":"Jenna","family":"Brager","sequence":"additional","affiliation":[{"name":"MyMD Pharmaceuticals, Inc. Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Chapman","sequence":"additional","affiliation":[{"name":"MyMD Pharmaceuticals, Inc. Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Dunn","sequence":"additional","affiliation":[{"name":"Clinical Research of West Florida Clearwater, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kaplin","sequence":"additional","affiliation":[{"name":"MyMD Pharmaceuticals, Inc. Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e006413","DOI":"10.1136\/bmjopen-2014-006413","article-title":"Risk of developing multimorbidity across all ages in an historical cohort study:\n                    differences by sex and ethnicity","volume":"5","author":"J L St Sauver","year":"2015","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"165612","DOI":"10.1016\/j.bbadis.2019.165612","article-title":"Current nutritional and pharmacological anti-aging interventions","volume":"1866","author":"M Ros","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s43587-020-00006-2","article-title":"Lifelong restriction of dietary branched-chain amino acids has sex-specific\n                    benefits for frailty and lifespan in mice","volume":"1","author":"N E Richardson","year":"2021","journal-title":"Nat Aging"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4049\/jimmunol.1801238","article-title":"MYMD-1, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis\n                    via Suppression of Th1 Responses and TNF-\u03b1 Release","volume":"202","author":"G Di Dalmazi","year":"2019","journal-title":"J Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"577115","DOI":"10.1016\/j.jneuroim.2019.577115","article-title":"MYMD-1, a novel alkaloid compound, ameliorates the course of experimental\n                    autoimmune encephalomyelitis","volume":"339","author":"J D Glenn","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00441-016-2511-x","article-title":"Mechanisms of lung aging","volume":"367","author":"C Brandenberger","year":"2017","journal-title":"Cell Tissue Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"glac142","DOI":"10.1093\/gerona\/glac142","article-title":"MyMD-1 improves health span and prolongs lifespan in old mice: A non-inferiority\n                    study to rapamycin","author":"E Sabini","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1962-6834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:44:33Z","timestamp":1675730673000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1962-6834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":7,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,2,6]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1962-6834","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}